BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E. Role of cetuximab in first-line treatment of metastatic colorectal cancer. World J Gastroenterol 2014; 20(15): 4208-4219 [PMID: 24764659 DOI: 10.3748/wjg.v20.i15.4208]
URL: https://www.wjgnet.com/1007-9327/full/v20/i15/4208.htm
Number Citing Articles
1
Mattan Levi, Aron Popovtzer, Moran Tzabari, Aviram Mizrachi, Naphtali Savion, Salomon M. Stemmer, Ruth Shalgi, Irit Ben-Aharon. Cetuximab intensifies cisplatin-induced testicular toxicityReproductive BioMedicine Online 2016; 33(1): 102 doi: 10.1016/j.rbmo.2016.04.004
2
Michel B. Choueiri, John Paul Shen, Andrew M. Gross, Justin K. Huang, Trey Ideker, Paul Fanta, Anthony W.I. Lo. ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon CancerPLOS ONE 2015; 10(6): e0126898 doi: 10.1371/journal.pone.0126898
3
Daniel C. Pan, Vinu Krishnan, Alyssa K. Salinas, Jayoung Kim, Tao Sun, Sagi Ravid, Kevin Peng, Debra Wu, Md Nurunnabi, Jeffery A. Nelson, Zachary Niziolek, Junling Guo, Samir Mitragotri. Hyaluronic acid–doxorubicin nanoparticles for targeted treatment of colorectal cancerBioengineering & Translational Medicine 2021; 6(1) doi: 10.1002/btm2.10166
4
Hui Sheng, Xiaoli Wei, Qunxi Chen, Kewei Huang, Runkun Han, Yijun Liu, Wen Liu, Minjie Mao, Arumugam R. Jayakumar. The Survival Advantage of Females at Premenopausal Age Is Race Dependent in Colorectal CancerBioMed Research International 2020; 2020: 1 doi: 10.1155/2020/7434783
5
Jian‐feng Yao, Xiao‐jun Li, Li‐kun Yan, Sai He, Jian‐bao Zheng, Xiao‐rong Wang, Pei‐hua Zhou, Li Zhang, Guang‐bing Wei, Xue‐jun Sun. Role of HGF/c‐Met in the treatment of colorectal cancer with liver metastasisJournal of Biochemical and Molecular Toxicology 2019; 33(6) doi: 10.1002/jbt.22316
6
Ya-Fan Yang, Gui-Ying Wang, Jing-Li He, Feng-Peng Wu, Yan-Ni Zhang. Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancerMedicine 2017; 96(12): e6335 doi: 10.1097/MD.0000000000006335
7
Jia-Xing Zhao, Li-Ren Liu, Xiao-Yu Yang, Fang Liu, Zhong-Guo Zhang. Serum CA19-9 as a marker of circulating tumor cells in first reflux blood of colorectal cancer patientsOncotarget 2017; 8(40): 67918 doi: 10.18632/oncotarget.18912
8
Juan W Valle. BINGO: targeted therapy for advanced biliary-tract cancerThe Lancet Oncology 2014; 15(8): 778 doi: 10.1016/S1470-2045(14)70238-4
9
Giulia Fornasier, Sara Francescon, Paolo Baldo. An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative ReviewAdvances in Therapy 2018; 35(10): 1497 doi: 10.1007/s12325-018-0791-0
10
Poojarani Panda, Henu Kumar Verma, Lakkakula V. K. S. Bhaskar. Precision Medicine Revolutionizing Esophageal Cancer Treatment: Surmounting Hurdles and Enhancing Therapeutic Efficacy through Targeted Drug TherapiesOnco 2023; 3(3): 127 doi: 10.3390/onco3030010
11
Feng Xiong, Yu-Wen Zhou, Ya-Ting Hao, Gui-Xia Wei, Xiao-Rong Chen, Meng Qiu. Combining Anti-epidermal Growth Factor Receptor (EGFR) Therapy with Immunotherapy in Metastatic Colorectal Cancer (mCRC)Expert Review of Gastroenterology & Hepatology 2024; 18(4-5): 185 doi: 10.1080/17474124.2023.2232718
12
Soudabeh Kavousipour, Fathemeh Khademi, Mozhdeh Zamani, Bahareh Vakili, Pooneh Mokarram. Novel biotechnology approaches in colorectal cancer diagnosis and therapyBiotechnology Letters 2017; 39(6): 785 doi: 10.1007/s10529-017-2303-8
13
Louisa Lo, Dainik Patel, Amanda R Townsend, Timothy J Price. Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancerExpert Opinion on Drug Metabolism & Toxicology 2015; 11(12): 1907 doi: 10.1517/17425255.2015.1112787
14
Ali Razaghi, Kirsten Heimann, Patrick M. Schaeffer, Spencer B. Gibson. Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapiesApoptosis 2018; 23(2): 93 doi: 10.1007/s10495-018-1440-4
15
Yue Wu, Haowei Jia, Xinqi Bao, Tianyu Zhu, Ruixin Li, Hongchao Zhao, Junfeng Sun. Gastrointestinal Disasters of Cetuximab in the Treatment of Metastatic Colorectal Cancer: Mechanism and its Effect on PrognosisAging Pathobiology and Therapeutics 2020; 2(2): 64 doi: 10.31491/APT.2020.06.016
16
Sirichat Kaowinn, Seung Won Jun, Chang Seok Kim, Dong-Myeong Shin, Yoon-Hwae Hwang, Kyujung Kim, Bosung Shin, Chutima Kaewpiboon, Hyeon Hee Jeong, Sang Seok Koh, Oliver H. Krämer, Randal N. Johnston, Young-Hwa Chung. Increased EGFR expression induced by a novel oncogene, CUG2, confers resistance to doxorubicin through Stat1-HDAC4 signalingCellular Oncology 2017; 40(6): 549 doi: 10.1007/s13402-017-0343-7
17
Nele Boeckx, Ken Op de Beeck, Vanessa Deschoolmeester, Guy Van Camp, Patrick Pauwels, Marc Peeters. Anti-EGFR Resistance in Colorectal Cancer: Current Knowledge and Future PerspectivesCurrent Colorectal Cancer Reports 2014; 10(4): 380 doi: 10.1007/s11888-014-0242-5
18
Daniel-Clement Osei-Bordom, Sivesh Kamarajah, Niki Christou. Colorectal Cancer, Liver Metastases and BiotherapiesBiomedicines 2021; 9(8): 894 doi: 10.3390/biomedicines9080894
19
Zhexuan Lin, Quanwei Zhang, Wenhong Luo. Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directionsEuropean Journal of Pharmacology 2016; 793: 76 doi: 10.1016/j.ejphar.2016.10.039
20
Anggraeni E. Kusumaningrum, Sarce Makaba, Eyhab Ali, Mandeep Singh, Mohammed N. Fenjan, Irodakhon Rasulova, Neeti Misra, Sada G. Al‐ Musawi, Ali Alsalamy. A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistanceCell Biochemistry and Function 2024; 42(1) doi: 10.1002/cbf.3906
21
Marc Peeters, Kelly S. Oliner, Timothy J. Price, Andrés Cervantes, Alberto F. Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, Andrew H. Strickland, Gregory Wilson, Tudor E. Ciuleanu, Laslo Roman, Eric Van Cutsem, Pei He, Hua Yu, Reija Koukakis, Jan-Henrik Terwey, Andre S. Jung, Roger Sidhu, Scott D. Patterson. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal CancerClinical Cancer Research 2015; 21(24): 5469 doi: 10.1158/1078-0432.CCR-15-0526
22
Long Bai, Feng Wang, Zhe-zhen Li, Chao Ren, Dong-sheng Zhang, Qi Zhao, Yun-xin Lu, De-shen Wang, Huai-qiang Ju, Miao-zhen Qiu, Zhi-qiang Wang, Feng-hua Wang, Rui-hua Xu. Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancerMedicine 2016; 95(51): e4531 doi: 10.1097/MD.0000000000004531